8-K: Day One Biopharma Q3 2025 Results: OJEMDA Revenue Soars

Day One Biopharmaceuticals reported strong third-quarter 2025 financial results, with OJEMDA net product revenue increasing 15% sequentially and full-year guidance raised.

Summary

• Day One Biopharmaceuticals announced its third quarter 2025 financial results and corporate progress.
• OJEMDA net product revenue for Q3 2025 was $38.5 million, a 15% increase from Q2 2025.
• Year-to-date U.S. OJEMDA net product revenue reached $102.6 million through Q3 2025, an 89% increase over fiscal year 2024.
• Quarterly prescriptions (TRx) for OJEMDA grew to 1,256 in Q3 2025, an 18% increase compared to Q2 2025.
• New patient starts for OJEMDA increased by 19% sequentially, driven by FIREFLY-1 clinical trial 2-year follow-up data.
• The company raised its full-year 2025 net product revenue guidance for OJEMDA to $145 million to $150 million.
• Ended the third quarter with $451.6 million in cash, cash equivalents, and short-term investments.
• Net loss for Q3 2025 was $19.7 million, compared to a net income of $37.0 million for Q3 2024 (which included significant license revenue).
• Research and development expenses decreased to $31.4 million in Q3 2025 from $33.6 million in Q3 2024.
• Selling, general and administrative expenses decreased to $28.1 million in Q3 2025 from $29.0 million in Q3 2024.
• Enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial is progressing, with completion anticipated in the first half of 2026.
• Dose escalation is advancing in the Phase 1a clinical trial of DAY301, a PTK7-targeted antibody drug conjugate (ADC).
• Tovorafenib was added as a Category 2a recommended therapy in the National Comprehensive Cancer Network (NCCN) treatment guidelines for adult patients with recurrent or progressive BRAF-altered glioma.
• Heather Adkins Huet, PhD, joined as Chief Scientific Officer in September 2025.

Sentiment

Score: 8

Explanation: The filing indicates strong commercial performance for OJEMDA, with significant sequential revenue and prescription growth, and a raised full-year guidance. Pipeline progress and a solid cash position further contribute to a very positive outlook, despite the reported net loss being influenced by one-time prior-year revenues.

Positives

• OJEMDA net product revenue grew 15% sequentially to $38.5 million in Q3 2025.
• Year-to-date U.S. OJEMDA net product revenue of $102.6 million represents an 89% increase over fiscal year 2024.
• Quarterly prescriptions (TRx) for OJEMDA increased by 18% to 1,256 in Q3 2025.
• New patient starts for OJEMDA grew 19% sequentially, indicating strong demand.
• Full-year 2025 OJEMDA net product revenue guidance was raised to $145 million to $150 million.
• Strong cash position of $451.6 million as of September 30, 2025.
• Tovorafenib (OJEMDA) was added to NCCN guidelines as a Category 2a recommended therapy for adult BRAF-altered glioma.
• Progress in pipeline with advancing enrollment in FIREFLY-2 and dose escalation in DAY301.
• Strong persistency observed with OJEMDA, with 20 months median duration of treatment for EAP patients and 75% of EAP patients reaching 24 months continuing treatment.
• High approval rate for on-label patients, with approximately 90% receiving approval on the first request.
• Increasing 2L adoption of OJEMDA, growing over 60% in the past 12 months.
• Significant repeat use by prescribers, with over 60% of accounts treating multiple patients and 28% sequential growth in accounts with 4 or more patients.

Negatives

• Net loss totaled $19.7 million for Q3 2025, a shift from a net income of $37.0 million in Q3 2024. This is primarily due to a significant decrease in license revenue from $73.7 million in Q3 2024 (including a $73.5 million upfront payment from Ipsen) to $1.3 million in Q3 2025.
• Nine months ended September 30, 2025, saw a net loss of $86.0 million, compared to a net loss of $29.8 million for the same period in 2024, indicating an increased year-to-date loss. The prior year period included a $108.0 million gain from the sale of a priority review voucher.

Risks

• Forward-looking statements involve risks and uncertainties, including Day One's ability to develop, obtain and retain regulatory approval for or commercialize any product candidate.
• Risks related to Day One's ability to protect intellectual property.
• Potential impact of global business or macroeconomic conditions, including inflation, changing interest rates, government shutdowns, cybersecurity incidents, significant political or regulatory developments or changes in trade policy, including tariffs.
• Shifting priorities within the U.S. Food and Drug Administration and reduced funding to federal healthcare programs.
• Global regional conflicts.
• Sufficiency of Day One's cash, cash equivalents and investments to fund its operations.
• Continued approval for OJEMDA's indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Future Outlook

The company anticipates continued strength in OJEMDA demand, leading to raised full-year 2025 net product revenue guidance of $145 million to $150 million. Enrollment completion for the pivotal Phase 3 FIREFLY-2 trial in first-line pediatric low-grade glioma is expected in the first half of 2026. The company is also advancing dose escalation for its Phase 1a clinical trial of DAY301 and expects a European Medicines Agency (EMA) regulatory decision for tovorafenib in 2026. Upcoming data from the FIREFLY-1 trial is expected to further strengthen the OJEMDA story and reinforce its target product profile.

Management Comments

• "Our third quarter results reflect acceleration across every key dimension of OJEMDAs performance and growing confidence among prescribers as we continue to build the case for second-line standard-of-care through execution and additional data readouts."
• "Combined with steady pipeline progress, we are well positioned to deliver sustainable growth for shareholders while we continue our mission to bring meaningful therapies to patients."
• "My default right now for second line is OJEMDA."
• "I've changed my practice recently and now offer OJEMDA after a patient fails chemotherapy."

Industry Context

Day One Biopharmaceuticals operates in the highly specialized and critical field of pediatric oncology, specifically targeting pediatric low-grade glioma (pLGG) with BRAF alterations. The success of OJEMDA (tovorafenib) in the relapsed/refractory setting, evidenced by strong revenue growth and increased prescriptions, positions the company as a significant player in this niche. The inclusion of tovorafenib in NCCN guidelines for adult BRAF-altered glioma also suggests broader recognition and potential for the drug. The advancement of DAY301, an ADC, aligns with a broader industry trend towards targeted therapies and ADCs in oncology, which are gaining traction due to their potential for improved efficacy and reduced systemic toxicity. The focus on unmet needs in pediatric cancer also highlights a growing area of investment and regulatory support within the pharmaceutical industry.

Comparison to Industry Standards

• The 15% sequential growth in OJEMDA net product revenue and 18% growth in prescriptions for a relatively new launch (approved April 2024, launched Dec 2024) demonstrates strong commercial uptake, which is generally considered robust for a specialized oncology drug, especially in a rare pediatric indication.
• The median duration of treatment of 20 months for EAP patients and 75% persistency at 24 months for OJEMDA indicates a durable response and patient adherence, which are favorable metrics compared to many oncology treatments where disease progression can be rapid.
• The NCCN Category 2a recommendation for tovorafenib in adult BRAF-altered glioma signifies a strong endorsement from a leading oncology guideline body, comparable to how other successful targeted therapies like BRAF/MEK inhibitors (e.g., dabrafenib/trametinib, vemurafenib) have been integrated into treatment paradigms for BRAF-mutated cancers.
• The development of DAY301, a PTK7-targeted ADC, positions Day One in a competitive space with other ADC developers like Seagen (now part of Pfizer) with Adcetris (CD30-targeted) or AstraZeneca/Daiichi Sankyo with Enhertu (HER2-targeted), aiming for improved therapeutic index over prior PTK7 ADCs like cofetuzumab pelidotin.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong commercial performance of OJEMDA, raised revenue guidance, and pipeline progress, potentially leading to increased shareholder value.
• Patients (Pediatric Low-Grade Glioma): Continued access to OJEMDA, a critical therapy, with ongoing clinical trials (FIREFLY-2) aiming to expand its use to first-line treatment, and new therapies like DAY301 in development.
• Healthcare Providers: Tovorafenib's inclusion in NCCN guidelines provides further validation and guidance for its use, potentially increasing prescriber confidence and adoption.
• Employees: Positive outlook due to company growth and pipeline advancements, potentially leading to job stability and opportunities.
• Regulatory Authorities: Ongoing engagement through clinical trials and regulatory submissions (e.g., EMA decision expected in 2026).

Next Steps

• Presentation of three-year data from the pivotal FIREFLY-1 trial at the 2025 Society for Neuro-Oncology Annual Meeting on November 23, 2025.
• Participation in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025.
• Continued enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial, with enrollment completion anticipated in the first half of 2026.
• Advancing dose escalation in the Phase 1a clinical trial of DAY301.
• Anticipated EMA regulatory decision for tovorafenib in 2026.
• Optimize persistence and drive new patient starts for OJEMDA.
• Strengthen the OJEMDA story through enhancing the target product profile and data generation.
• Establish OJEMDA as the standard of care in second-line relapsed/refractory BRAF-altered pLGG.
• Leverage development and commercialization expertise to further expand the multiple asset portfolio.
• Maintain a strong capital position while investing in the pipeline.

Key Dates

Recommendation

The company demonstrates exceptional commercial execution for OJEMDA, significantly exceeding prior performance metrics and raising full-year revenue guidance. The strong cash position, coupled with promising pipeline advancements for FIREFLY-2 and DAY301, indicates robust growth potential. While the net loss increased year-over-year, this is primarily due to the absence of one-time license revenue and a priority review voucher sale from the prior year, rather than operational underperformance. The positive momentum in market adoption, physician confidence, and strategic pipeline development makes Day One Biopharmaceuticals a compelling investment opportunity.

Keywords

Day One Biopharmaceuticals, DAWN, OJEMDA, tovorafenib, pediatric low-grade glioma, pLGG, BRAF-altered glioma, oncology, biopharmaceutical, financial results, Q3 2025, FIREFLY-1, FIREFLY-2, DAY301, antibody drug conjugate, ADC, PTK7, cancer therapy, clinical trials, drug development, biotech, pharmaceuticals